Key Takeaways
- AstraZeneca is considering a $400bn merger with Bristol Myers Squibb.
- The deal would create the world’s fourth-largest pharmaceutical company.
- Pascal Soriot, CEO of AstraZeneca, leads the discussions.
British drugmaker AstraZeneca is in advanced talks to acquire its US rival Bristol Myers Squibb, a move that could value the combined entity at nearly $400 billion (£300 billion).
If successful, this deal would position the merged company as one of the world’s largest pharmaceutical firms, following closely behind giants like Pfizer and Merck.
Pascal Soriot, CEO of AstraZeneca, is overseeing these negotiations. The UK-based firm, known for its significant contributions to global healthcare, currently holds a market value of nearly £196 billion.
